CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 33 enrolled
Drug / intervention
Oxaloacetate (OAA) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01741701
NCT01741701Phase 3Completed
CompareCT.gov

A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)

University of Kansas Medical Center·interventional·Posted Dec 5, 2012·Updated Mar 17, 2016

In Brief

A Phase 3 clinical trial evaluating Oxaloacetate (OAA) and Placebo for Parkinson's Disease. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4 month period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
CollaboratorsTerra Biological LLC

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2012
Enrollment StartDec 1, 2012
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.6 years ago

Interventions

Oxaloacetate (OAA)drug

Placebodrug